Physician profile
Stephen Beasley
NPI 1568897668
$6,616.62
in general payments reported to CMS, 2019-2025
36 companies · $822 in 2025
The $822 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $624 · 2021: $1,426 · 2022: $895 · 2023: $1,314 · 2024: $1,211 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.15 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $578.58 | 2020-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $494.41 | 2021-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $410.70 | 2019-2024 | Ocaliva |
| Celgene Corporation | $272.67 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $253.04 | 2019-2024 | |
| Lilly USA, LLC | $224.26 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.68 | 2020-2024 | Xifaxan, Plenvu, Trulance |
| Medtronic, INC. | $150.31 | 2021-2025 | Interstim, Gi Genius |
| Ardelyx, INC. | $143.79 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $140.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $124.01 | 2023-2025 | Dupixent |
| Daiichi Sankyo INC. | $120.27 | 2020-2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $100.00 | 2023 | Zeposia |
| Pfizer INC. | $92.40 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $78.66 | 2020-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $69.57 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $67.37 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $63.99 | 2023 | Idacio |
| Braintree Laboratories, INC. | $60.56 | 2020-2025 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $53.53 | 2020-2022 | |
| Qol Medical, LLC | $46.26 | 2021 | |
| Phathom Pharmaceuticals, INC. | $40.46 | 2025 | Voquezna |
| Amgen INC. | $36.86 | 2020-2022 | |
| Redhill Biopharma INC. | $36.75 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $25.56 | 2023 | Rebyota |
| Genzyme Corporation | $25.12 | 2024 | |
| Mauna Kea Technologies, INC. | $19.92 | 2024 | |
| Mallinckrodt Hospital Products INC. | $17.36 | 2025 | Terlivaz |
| Evoke Pharma, INC. | $17.34 | 2022 | |
| Vivus LLC | $17.20 | 2021 | |
| Intra-Sana Laboratories | $14.54 | 2021 | |
| Ucb, INC. | $13.53 | 2020 | |
| Ethicon US, LLC | $13.16 | 2022 | |
| Organon LLC | $11.94 | 2025 | Renflexis, Hadlima |
| Alfasigma USA, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.